Podcasts about ozanimod

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Alcibiades Rodriguez, MD, medical director of the Comprehensive Epilepsy Center—Sleep Center at NYU Langone discussed several sleep-related topics, including the diagnosis of rare sleep disorders and hypersomnias. He spoke on the treatment of obstructive sleep apnea, the importance of adherence to medication, and the ways clinicians can help patients stick to their treatment regimen. Furthermore, he talked about the conversations between patients and clinicians to ensure an accurate diagnosis, as well as the emerging research in the sleep disorder field over the coming years. Looking for more sleep disorders discussion? Check out the NeurologyLive® sleep disorders clinical focus page. Episode Breakdown: 1:40 – Conversations needed to differentiate diagnoses 4:30 – Appearance of sleep disorders and overlap 6:50 – Complications with untreated sleep apnea 8:25 – Neurology News Minute 10:55 – Ways to improve adherence to medication 13:50 – Emerging research in the field This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Glatiramer Acetate Depot Demonstrates Sustained Longterm Safety Profile as Potential MS Therapy Phase 3 DAYBREAK Trial Highlights Long-Term Efficacy of Ozanimod for Relapsing Multiple Sclerosis SRP-9001 Improves Duchenne Muscular Dystrophy Disease Trajectory Despite Failing to Meet Primary End Point in Phase 3 EMBARK Trial Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In this episode of IBD Drive Time, Drs Millie Long and Raymond Cross, talk to Dr Sara Horst as they recap the abstract from the ECCO'23 Congress on ozanimod to help listeners understand how to utilize the drug to achieve better clinical responses in treating inflammatory bowel disease. Raymond Cross, MD, is professor of medicine and director of the IBD Program at the University of Maryland School of Medicine in Baltimore, Maryland. Millie Long, MD, is a professor of medicine, vice chief of education and director of the fellowship program in the Division of Gastroenterology and Hepatology at the University of North Carolina at Chapel Hill. Sara Horst, MD, is an associate professor of medicine Vanderbilt University and a specialist in the treatment of IBD.

This is my review of Zeposia (Ozanimod), a new once a day oral medication for moderate to severe ulcerative colitis. I go over the True North Study (https://www.nejm.org/doi/full/10.1056/NEJMoa2033617) in detail including efficacy and safety data. I have no conflicts of interest with any pharmaceutical companies. These are my opinions regarding Zeposia and other medications based on my personal/clinical experience and review of the literature. 

Hey everyone. Today we welcome Harlan Muir to the show. Harlan is a sufferer of Ulcerative Colitis, and he sat down to talk to Ellen and Dave about the painful ins and crazy out of this condition. For those out there suffering from UC, there is hope. A new drug called Ozanimod, should be on the market soon, and it has all but cured Harlan from the effects of UC. Sit back and enjoy   Follow Hey Poopy Podcast at: Instagram @heypoopypodcast Twitter @HeyPoopy YouTube Hey Poopy Dave Ellen Website www.heypoopypodcast.com Email heypoopypodcast@gmail.com Call Us at 203-998-5579

This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola. 

The National MS Society's National Medical Advisory Committee has issued its recommendations for MS disease-modifying therapies and the coronavirus (COVID-19), and we're sharing them in this episode. You'll also hear about a new disease-modifying therapy that's about to receive FDA approval. We'll tell you about a clinical trial for a potential disease-modifying therapy for progressive MS that fell short of achieving its goals. And you'll hear about study results that indicate there are still a lot of people living with MS who aren't acting in their own best interest.   My guest this week is Dawnia Baynes. Besides being an MS Activist, Dawnia facilitates a very special MS support group, and last month, the Southern-California Nevada Chapter of the National MS Society named Dawnia their Inspirational Person of the Year. We have a lot to talk about! Are you ready for RealTalk MS??! ___________   Make sure you're getting your COVID-19 info from credible sources   :39 The Coronavirus (COVID-19) and MS Disease-Modifying Therapies  2:41 Ozanimod scheduled for FDA Approval this Month  2:09 High-Dose Biotin For Progressive MS Fails to Improve Disability  7:41 Disease-Modifying Therapy Non-Compliance Among People Living with MS  9:07 My Interview with Dawnia Baynes  12:05 Share this Episode  24:26 Reminder...Please Donate to Walk-MS  24:46 ___________ SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/133 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com What You Need to Know About Coronavirus (COVID-19) MS Disease-Modifying Treatment Guidelines for Coronavirus (COVID-19) Non-Compliance With Disease-Modifying Therapies in Patients With Multiple Sclerosis: A Qualitative Analysis Support Group for Teens Living with MS  Jon's WALK-MS Fundraising Page Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 133 Hosted By: Jon Strum Guests: Dawnia Baynes Tags: MS, MultipleSclerosis, MSResearch, MSActivist, MSSociety, Coronavirus, COVID-19, RealTalkMS Privacy Policy

If someone is being treated for MS, their neurologist is using the Expanded Disability Status Score, or EDSS, to indicate their level of disability. What if there were a better, easier, and more accurate way to measure mobility and evaluate disability?      My guest today is Dr. Valerie Block, a Postdoctoral Fellow in the Department of Neurology at University of California San Francisco.  As a physical therapist, Dr. Block is focused on MS rehabilitation. And we're talking about a just-published study that demonstrates that the way neurologists measure disability may not be providing a complete and accurate picture...and there may be a much better way to get that done.   We're also talking about a new effort to eliminate the Affordable Care Act and strip away all of its protections for people living with MS and every other chronic illness -- and how the National MS Society and 25 other national patient organizations are fighting back by supporting new legislation designed to strengthen the ACA.    We'll tell you about the TWO!!! MS prescription medications that just received FDA approval, and we'll even tell you about yet another MS prescription medication that's now awaiting FDA approval.   We have a lot to talk about! Are you ready for RealTalk MS?!   ___________ RealTalk MS Reaches a Milestone  :26 Join the RealTalk MS Conversation  :48 Living with MS? Your Access to Healthcare is Under Attack ...Again!  2:53 Mavenclad Receives FDA Approval for Treating Relapsing-Remitting and Active Secondary Progressive MS  11:37 Siponimod Receives FDA Approval for Treating Relapsing-Remitting and Active Secondary Progressive MS 15:01 Celgene Submits Application for FDA Approval of Ozanimod for Treating Relapsing-Remitting MS  16:41 My Interview with Dr. Valerie Block  19:16 Download the Free RealTalk MS App  34:04 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jonstrum@RealTalkMS.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review 26 Patient Groups Support Bill to Stabilize and Strengthen the Affordable Care Act   FDA Approves New Oral Treatment for Multiple Sclerosis   FDA Approves New Oral Drug to Treat Multiple Sclerosis ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 84 Hosted By: Jon Strum Guest: Dr. Valerie Block Tags: MS, MultipleSclerosis, MSResearch, ProgressiveMS, Mavenclad, EMDSerono, Siponimod, Novartis, Celgene, RealTalkMS

MS is an equal opportunity neurological disease. It doesn't seem to discriminate against any particular ethnic or racial group. It affects Latinos and African-Americans, as well as Caucasians. And if you're an MS research scientist, who's hoping to create a viable treatment that's going to be safe & effective for the diverse population living with multiple sclerosis, then having that diversity represented in your clinical research seems like it would be important. Unfortunately, it doesn't always happen that way. Minority populations are frequently overlooked and under-represented in MS clinical research.   My guest on the podcast is Dr. Mitzi Joi Williams, a neurologist and MS Specialist with a strong interest in better understanding the course of MS in ethnic minority populations, and in increasing diversity in clinical research.      We're also talking about important MS stem cell research that's being funded by the Department of Defense, the risks associated with stem cell tourism, a new oral Disease Modifying Therapy for relapsing-remitting MS, and a newly-approved prescription medication for treatment-resistant depression.   We have a lot to talk about! Are you ready for RealTalk MS?!   ___________ Promising MS Stem Cell Research Funded by Department of Defense  1:33 National MS Society Announces Strategic Partnership with U.S. Department of Veteran Affairs  4:32 The Risks of Stem Cell Tourism 5:26 Celgene Seeks EMA Approval of Ozanimod  11:29 FDA Approves Esketamine for Treatment-Resistant Depression  12:50 My Interview with Dr. Mitzi Joi Williams  16:27 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jonstrum@RealTalkMS.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review Using Reprogrammed Stem Cells as a Therapy for MS Complications of Stem Cell Tourism in Multiple Sclerosis & Other Neurological Diseases: Results From First Nationwide Survey of Academic Neurologists Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis FDA Approves Esketamine Nasal Spray for Treatment of Resistant Depression MS Made Simple by Dr. Mitzi Joi Williams ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 82 Hosted By: Jon Strum Guest: Dr. Mitzi Joi Williams Tags: MS, MultipleSclerosis, MSResearch, mssociety, Ozanimod, Esketamine, iConquerMS, Stemcells, RealTalkMS

Dr. Peter Higgins of the University of Michigan IBD Center is our special guest this month. Dr. Higgins talks to us about the latest IBD research that is going on.. New IBD drugs that have just come to market Ozanimod and Mongersen.. Can you have both Crohn’s Disease and Ulcerative Colitis? The 23andMe Study, The […] The post Episode 14 – FAQ with Dr Peter Higgins appeared first on The Crohn's Colitis Effect.